Glial fibrillary acidic protein: A marker of axonal Guillain-Barrè syndrome and outcome

Muscle and Nerve

Volumn 38, Issue 1, 2008, Pages 899-903

  Notturno, Francesca ^a   Caporale, Christina M ^a   De Lauretis, Angelo ^b   Uncini, Antonino ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Axonal GBS; Diagnostic marker; Glial fibrillary acidic protein; Outcome

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AXONAL GUILLAIN BARRE SYNDROME; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ACTION POTENTIALS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; DATA INTERPRETATION, STATISTICAL; ELECTROMYOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; MOTOR NEURONS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TREATMENT OUTCOME;

EID: 46249085917     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20983     Document Type: Article

References (30)

1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for GBS. Ann Neurol 1990;27(Suppl):S21-24.
2. Autilo-Gambetti L, Sipple J, Sudilowski O, Gambetti P. Intermediate filaments of Schwann cells. J Neurochem 1982;38: 774-780.
3. Bianchini D, De Martini I, Cadoni A, Zicca A, Tabaton M, Schenone A, et al. GFAP expression of human Schwann cells in tissue culture. Brain Res 1992;20:209-217.
4. Brisby H, Olmarker K, Rosengren L, Cederlund CG, Rydevik B. Markers of nerve tissue injury in the cerebrospinal fluid in patients with lumbar disc herniation and sciatica. Spine 1999; 24:742-746.
5. Cheng C, Zochodne DW. In vivo proliferation, migration and phenotypic changes of Schwann cells in the presence of myelinated fibers. Neuroscience 2002;115:321-329.
6. Feasby TE, Gilber JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain 1986;109:1115-1126.
7. Fields K, Yen SH. A subset of Scwann cells in peripheral nerves contain a 50-hDa protein antigenically related to astrocyte intermediate filaments. J Neuroimmunol 1985;8:311-330.
8. Griffin JW, Stocks EA, Fahnestock K, Van Praagh A, Trapp BD. Schwann cell proliferation following lysolecithin-induced demyelination. J Neurocytol 1990;19:367-384.
9. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical association and outcome. Ann Neurol 1998;44:780-788.
10. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000;31: 2670-2677.
11. Ho TW, Hsieh ST, Nachamkin I, Willison HJ, Sheikh K, Kiehlbatich J, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1998;48:717-724.
12. Hughes RAC, Newsom-Davies JM, Perkins GD. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2:750-753.
13. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-1666.
14. Jessen KR, Mirsky R. Non-myelin-fornring Schwann cells co-express surface proteins and intermediate filaments not found in myelin-forming cells: a study of Ran-2, A5E3, antigen and glial fibrillary acidic protein. J Neurocytol 1984;13:923-934.
15. Jessen KR, Morgan L, Stewart HJS, Mirsky R. Three markers of adult non-myelin-forming Schwann cells, 217c (Ran-1), A5E3 and GFAP: development and regulation by neuron-Schwann cell interactions. Development 1990;109:91-103.
16. Jessen KR, Mirski R. Schwann cells and their precursors emerge as major regulators of nerve development. Trends Neurosci 1999;22:402-410.
17. Malmeström M, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;1720-1725.
18. Mancardi GL, Cadoni A, Tabaton M, Schenone A, Zicca A, De Martini I, et al. Schwann cell GFAP expression increases in axonal neuropathies. J Neurol Sci 1991;102:177-183.
19. McKhann GM, Cornblath DR, Ho T, Li CY, Bai AY, Wu HS, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-597.
20. Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004;1586-1590.
21. O'Brien MD. Aids to the examination of the peripheral nervous system. Edinburgh: W.B. Saunders (on behalf of the Guarantors of Brain); 2000.
22. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-1473.
23. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ. An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004;287:169-177.
24. Quattrini A, Previtali S, Feltri ML, Canal N, Nemni R, Wrabetz L. Beta 4 integrin and other Schwann cell markers in axonal neuropathy. Glia 1996;17:294-306.
25. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197-204.
26. Toews AD, Griffiths IR, Kyriakides E, Goodrum JF, Eckermann CE, Morell P, et al. Primary demyelination induced by exposure to tellurium alters Schwann cell gene expression: a model for intracellular targeting of NGF receptor. J Neurosci 1992;12:3676-3687.
27. Triolo D, Dina G, Lorenzetti I, Malaguti M, Morana P, Del Carro U, et al. Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. J Cell Sci 2006;119:3981-3993.
28. Van Geel WJ, de Reus HPM, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 2002;326:151-154.
29. Van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, van Doom PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589-594.
30. Vos PE, Lamers KJB, Hendriks JC, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004;62:1303-1310.